This website is optimized for visualization with Firefox and Internet Explorer (8 or 9)

CLINICAL DEVELOPMENT PIPELINE

Regulatory Review

Phase III

Phase II

  • IL-23 antibody
    LY3074828 (IL-23 antibody) is a biologic entity that blocks the activity of the cytokine interleukin 23. LY3074828 is being studied for the treatment of ulcerative colitis.

    For more information on LY3074828 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • BMP-6 MAb anemia
    LY3113593 (BMP-6 antibody) is a fully humanized antibody that binds to the bone morphogenetic protein-6 and inhibits its activity. LY3113593 is being studied for the treatment of anemia. For more information on LY3113593 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • PCSK9 Monoclonal Antibody
    LY3015014 (PCSK9 monoclonal antibody) is a biologic entity that binds to and inhibits the activity of proprotein convertase subtilisin/kexin type 9. LY3015014 is being studied for the treatment of cardiovascular disease.

    For more information on LY3015014 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.


     
  • Ultra Rapid Insulin
    URI is pursued pre-FRD through two approaches, BioChaperone insulin lispro in collaboration with Adocia and an internal ultra-rapid formulation project of insulin lispro. Both projects are biologic entities being studied for the treatment of type 1 and type 2 diabetes.

    For more information on BioChaperone Lispro clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Myostatin Monoclonal Antibody
    LY2495655 (myostatin monoclonal antibody), a biologic entity, is a fully humanized antibody that inhibits myostatin activity. LY2495655 is being studied for the treatment of disuse muscle atrophy.

    For more information on LY2495655 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • CXCR4 Peptide Antagonist
    LY2510924 (CXCR4 peptide antagonist) is a biologic entity that antagonizes ligand binding to the CXC chemokine receptor 4. LY2510924 is being studied for the treatment of cancer.

    For more information on LY2510924 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Emibetuzumab (em” i be tooz’ ue mab)
    LY2875358 (formerly known as c-Met antibody), a biologic entity, was designed as a bivalent c-Met antibody that has neutralization and internalization activity with minimal agonistic activity. LY2875358 is being studied for the treatment of NSCLC.

    For more information on LY2875358 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase I

  • GIP/GLP-1 Co-agonist Peptide
    "GIP/GLP-1 Co-agonist Peptide" is a new biologic entity being studied for the treatment of diabetes.

     
  • hypoglycemia
    New biologic entity.

     
  • Blosozumab (bloe soz' ue mab)
    LY2541546 (blosozumab) is a new biologic entity that binds and neutralizes sclerostin. LY2541546 is being studied as a treatment for osteoporosis.

     
  • BAFF/IL-17 Bispecific Antibody
    "BAFF/IL-17 Bispecific Antibody" is a new biologic entity being studied for the treatment of immune diseases.

     
  • CXCR1/2 Ligands Antibody
    "CXCR1/2 Ligands Antibody" is a new biologic entity being studied for the treatment of immune diseases.

     
  • IL-21 Antibody
    "IL-21 Antibody" is a new biologic entity being studied for the treatment of immune diseases.

     
  • A ß antibody Fab PEG Alzheimer's
    "A b Antibody Fab PEG" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • N3pG-Aß Monoclonal Antibody
    "N3pG-Aß Monoclonal Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • Tau Antibody
    "Tau Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • Angiopoietin 2 MAb cancer
    "Angiopoietin 2 Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  • CSF-1R Monoclonal Antibody
    "CSF-1R Monoclonal Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  • FGFR3-ADC cancer
    "FGFR3-ADC" is a new biologic entity being studied for the treatment of cancer.

     
  • Met/EGFR Bispecific Antibody
    "Met/EGFR Bispecific Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  • PD-L1 Antibody
    "PD-L1 Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Pipeline Disclaimer
The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently-approved products, that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued, delayed or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of July 19, 2016. Lilly assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.
  • NME
  • Select NILEX
  • Diagnostic